This Article Full Text Full Text (PDF) Perspective on this Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tang, X. Articles by Wistuba, I. I. Search for Related Content PubMed PubMed Citation Articles by Tang, X. Articles by Wistuba, I. I. Related Collections Oncogenesis Oncogenesis: Biomarkers Oncogenesis: Clinical Models

Epidermal Growth Factor Receptor Abnormalities in the Pathogenesis and Progression of Lung Adenocarcinomas

Authors' Affiliations: Departments of ¹ Thoracic/Head and Neck Medical Oncology and ² Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, and ³ Department of Medicine/Medical Oncology and Pathology, University of Colorado Cancer Center, Aurora, Colorado

Requests for reprints: Ignacio I. Wistuba, Department of Pathology, Unit 85, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009. Phone: 713-563-9184; Fax: 713-792-0309; E-mail: iiwistuba{at}mdanderson.org.

To identify the characteristics and sequence of epidermal growth factor receptor (EGFR) abnormalities relevant to the pathogenesis and progression of lung adenocarcinoma, we performed a precise mapping analysis of EGFR mutation, gene copy number, and total and phosphorylated EGFR protein expression for the same tissue sites. We examined normal bronchial and bronchiolar epithelium (NBE) and tumor tissues obtained from 50 formalin-fixed lung adenocarcinomas, including 24 EGFR-mutant primary tumors with nine corresponding lymph node metastases and 26 wild-type primary tumors. NBE in 12 of 24 (50%) mutant and 3 of 26 (12%) wild-type tumors harbored EGFR mutations; these NBE also showed a lack of EGFR copy number increase and frequent EGFR (69%) and phosphorylated EGFR (33%) overexpression. EGFR mutation and protein overexpression were more frequent in NBE sites within tumors than in NBE sites adjacent to and distant from tumors, suggesting a localized field effect. Sites with high and low EGFR copy numbers were heterogeneously distributed in six of nine primary tumors and in one of eight metastases. EGFR protein overexpression was significantly higher in metastasis sites than in primary tumors. We conclude from our findings that EGFR mutations and protein overexpression are early phenomena in the pathogenesis of lung adenocarcinoma and that EGFR mutation precedes an increase in gene copy number. In EGFR-mutant adenocarcinoma metastases, the higher levels of EGFR overexpression and more homogeneously distributed high gene copy numbers suggest tumor progression. Our findings have important implications for the development of new strategies for targeted chemoprevention and therapy in lung adenocarcinoma using EGFR inhibitors.

Key Words: EGFR • FISH • Microdissection

This article has been cited by other articles:

				M. Doubrovin, T. Kochetkova, E. Santos, D. R. Veach, P. Smith-Jones, N. Pillarsetty, J. Balatoni, W. Bornmann, J. Gelovani, and S. M. Larson 124I-Iodopyridopyrimidinone for PET of Abl Kinase-Expressing Tumors In Vivo J. Nucl. Med., January 1, 2010; 51(1): 121 - 129. [Abstract] [Full Text] [PDF]

				A. S. Tsao, D. Liu, J. Martin, X.-m. Tang, J. J. Lee, A. K. El-Naggar, I. Wistuba, K. S. Culotta, L. Mao, A. Gillenwater, et al. Phase II Randomized, Placebo-Controlled Trial of Green Tea Extract in Patients with High-Risk Oral Premalignant Lesions Cancer Prevention Research, November 1, 2009; 2(11): 931 - 941. [Abstract] [Full Text] [PDF]